{"release":"wpf-claim-checks","version":"1.6.0","checkedOn":"2026-11-14","verificationLabel":"AI-assisted source verification","humanReview":"none recorded","claim":{"id":"approved-medicine-evidence-same-peptide-name","claimWording":"Studies of an approved semaglutide medicine apply automatically to any product called semaglutide.","wordingKind":"representative","quoted":null,"title":"Evidence for an approved medicine and other products with the same peptide name","peptides":["semaglutide","liraglutide"],"aliases":["Wegovy","Ozempic","Victoza","Saxenda","compounded semaglutide","generic liraglutide","salt form"],"topics":["regulatory","identity","interpretation"],"verdict":"overstated","plainAnswer":"The trials behind an approved medicine tested that medicine. Their results carry over to another product only when a regulator has found the two equivalent, which is how an FDA-approved generic is judged against a named reference product. FDA states that compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before they are marketed, so such a product does not inherit the trial evidence through its name.","scope":{"population":"US-regulated injectable semaglutide (Wegovy) and liraglutide (Victoza as the reference product for an approved generic)","design":"Comparison of an FDA-approved product label, FDA statements on compounded drugs, FDA requirements for generic drugs and an FDA approval record","boundary":"United States only, on the dates checked. It concerns whether trial evidence transfers, not the content, quality or safety of any specific product, which WPF did not test. It is not advice about any product, and regulatory status is not scientific evidence. Online \"research\" products are covered by the check on research-use-only labelling."},"strongest":[{"label":"WEGOVY (semaglutide) injection label, Novo Nordisk, DailyMed set ID ee06186f-2aa3-4990-a760-757579d8f77b, version 19, published 2026-06-30 (label revised 06/2026)","url":"https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b","kind":"Regulatory document","population":"Adults with obesity or overweight and established cardiovascular disease (Study 1)","design":"FDA-approved prescribing information, Clinical Studies section","locator":"Section 14.1: \"Study 1 (NCT03574597) was a multi-national, multi-center, placebo-controlled, double-blind trial to determine the effect of WEGOVY injection relative to placebo on major adverse CV events\"."},{"label":"FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 10/01/2026)","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","kind":"Regulatory document","population":"Compounded GLP-1 drugs, including compounded semaglutide","design":"FDA statement","locator":"Section \"Concerns with compounded versions of these drugs\": \"compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.\" Section \"Salt forms should not be used to compound semaglutide\": \"some semaglutide products sold by compounders may be the salt forms.\""},{"label":"FDA, FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (content current as of 07/26/2024)","url":"https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded","kind":"Regulatory document","population":"Compounded semaglutide products","design":"FDA alert","locator":"Paragraph beginning \"FDA had also received reports that in some cases, compounders may be using salt forms of semaglutide\": \"The salt forms are different active ingredients than is used in the approved drugs, which contain the base form of semaglutide.\""},{"label":"FDA, Generic Drugs: Questions & Answers (content current as of 09/18/2026)","url":"https://www.fda.gov/drugs/generic-drugs/generic-drugs-questions-answers","kind":"Regulatory document","population":"FDA-approved generic drugs in general","design":"FDA explanatory page","locator":"\"ANDAs must show, among other things, the generic drug is pharmaceutically equivalent and bioequivalent to the brand name drug it references\"; \"Generic drug companies do not need to repeat the costly clinical trials that establish a drug's safety and effectiveness. Instead, the generic drug manufacturer assures safety and effectiveness by demonstrating that their product is therapeutically equivalent to the brand drug.\""},{"label":"FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes (2024-12-23) and Drugs@FDA record ANDA215503","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes","kind":"Regulatory document","population":"Generic liraglutide injection referencing Victoza","design":"FDA approval announcement; Drugs@FDA record read through the openFDA API","locator":"Announcement: \"the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter\", approval granted to Hikma Pharmaceuticals USA Inc. openFDA drugsfda record ANDA215503: sponsor HIKMA, liraglutide solution for subcutaneous use, original action 2024-12-23, marketing status Prescription."}],"uncertain":["These are regulator statements about status and process, not measurements of what any particular product contains or how it behaves.","FDA's wording on salt forms is conditional (\"may be\"). WPF did not verify how many products are salt forms.","FDA's statements describe compounded drugs as a category. They do not say any specific compounded product is unsafe or ineffective, and this check does not either.","The generic-drug page is general and not specific to liraglutide, and the approval announcement does not itself state the equivalence standard.","Other regulators' rules were not checked and can differ."],"wouldChange":["Bioequivalence or clinical data for a specific non-approved product, which would speak to that product only.","An FDA approval of a product as a generic of a named reference product, which by FDA's description lets the reference product's evidence stand for it.","A change in FDA's published position on compounded products."],"gaps":["The label was read on DailyMed (National Library of Medicine, which publishes FDA-submitted labels), not on Drugs@FDA.","Only one approved-generic example (liraglutide) was read in detail; WPF did not search for approved generics of other peptide medicines.","Products sold online as \"research\" peptides are not addressed here; see the research-use-only check."],"searchScope":null,"regulatory":{"product":"Liraglutide injection (generic), ANDA215503, referencing Victoza","indication":"To lower blood sugar in patients with type 2 diabetes (as stated in the announcement title)","jurisdiction":"United States (FDA)","decisionType":"Approval of a generic drug (abbreviated new drug application)","decisionDate":"2024-12-23","officialSource":{"label":"FDA announcement of the first generic referencing Victoza","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes"}},"checkedOn":"2026-11-14","links":{"profiles":["/directory/semaglutide"],"films":[],"flagship":[],"journeys":["/research/journey/semaglutide"],"teaching":[],"changes":["/research/changes#regulatory_decision"]},"extends1_0_0":false},"sha256":"7c89da4569d2077397304567140d9acce3077635399099321a925855a68443bd"}